Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196. SH; 02196. HK) today revealed an H share redeemed strategy, under which the business plans to redeem its H show an aggregate quantity of approximately HK$ 1 billion. The shares so bought will be cancelled or held as treasury shares. Taking concrete action to react to market issues, this bought strategy shows management’s undeviating self-confidence in the business’s intrinsic worth. The strategy has actually entered into result and will be carried out as quickly as practicable. As an extension of the Group’s long-lasting worth management toolkit, the business will dynamically assess and carry out repurchases on a rolling basis in action to market conditions, developing a stabilized system for investor returns.
In the very first half of 2026, Fosun Pharma’s incomes quality continued to enhance, with income contributions from ingenious drugs and worldwide markets progressively increasing. Core functional signs even more combined upon the structure of 2025:
– Profits: RMB 20,442 million, up 4.75% year-on-year;
– Revenue attributable to investors of the noted business, web of non-recurring gains and losses: RMB 1,144 million, up 19.09% year-on-year;
– Net money produced from running activities: RMB 2,424 million, up 13.59% year-on-year.
The repurchase will be mostly moneyed by profits from the disposal of around 6.00% equity interest in Gland Pharma, with overall factor to consider of around US$ 294 million. Upon conclusion of the deal, Fosun Pharma stays the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be combined into Fosun Pharma’s monetary declarations. Net earnings from the deal will mostly be designated towards the Company’s R&D financial investments, share repurchases, and the payment of interest-bearing financial obligations. As the managing investor, Fosun Pharma stays totally positive in Gland Pharma’s long-lasting advancement and its long-lasting function as a crucial engine for abroad worth production.
Looking ahead, Fosun Pharma will remain concentrated on development and globalization, speeding up the R&D development and commercialization of its significant pipeline prospects. This redeemed program is meant to communicate the Company’s self-confidence in its intrinsic worth and to produce sustainable returns for investors.
About Fosun Pharma
Established in 1994, Fosun Pharma (stock code: 600196. SH; 02196. HK) is an innovation-driven worldwide pharmaceutical and health care group. With the objective of Better Health for Families Worldwide, we concentrate on establishing ingenious medications, medical innovations and diagnostics in addition to providing health care services. Through our organization partner Sinopharm Group, we have actually likewise developed pharmaceutical circulation network, constructed an extensive pharmaceutical and health care community.
Fosun Pharma is committed to development and globalization. The business has actually developed a worldwide R&D development system targeting at unmet medical requirements. Our tactical focus is on crucial restorative locations consisting of oncology, immunology and swelling, neurodegenerative illness, and picked cardiometabolic illness and unusual illness. This technique makes it possible for the advancement of high valued competitive pipelines and extensive health care services. Fosun Pharma has actually combined its core technical platforms consisting of however not restricted to antibodies and antibody-drug conjugates (ADC), little particles and cell treatment. In addition, we likewise actively advance advanced healing methods such as radiopharmaceuticals and little nucleic acids. These efforts have actually reinforced our early-stage ingenious portfolios and sped up the improvement of clinical discoveries to drug advancement. Our ingenious items are now readily available in more than 90 nations and areas worldwide, consisting of significant markets throughout China, the United States, Europe, Africa, India and Southeast Asia.
Looking ahead, assisted by the technique of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma stays dedicated to its core worths: Care for life, Continuous development, Pursuit of quality and Sustainable collaboration. We make every effort to end up being a leading worldwide health care development integrator, guaranteeing that the advantages of medical development reach more clients worldwide, and add to protecting human health.
To find out more about the Group, please go to the business site:
https://www.fosunpharma.com/en/
Subject: Press release summary